(INMD) InMode - Ratings and Ratios
Medical Devices, Aesthetic Products, RF Technology, Liposuction, Skin Tightening
INMD EPS (Earnings per Share)
INMD Revenue
Description: INMD InMode
InMode Ltd is a medical technology company that specializes in developing and marketing innovative, minimally invasive aesthetic medical products. Their proprietary technologies, including radio frequency assisted lipolysis and deep subdermal fractional radiofrequency, are used in a range of procedures such as body contouring, skin rejuvenation, and hair reduction. With a global presence, InModes products are sold in numerous countries, including the US, Europe, Japan, Australia, and India, through a network of distributors.
The companys product portfolio is diverse, catering to various aesthetic and medical needs, including liposuction, skin tightening, and womens health conditions. InModes non-invasive and hands-free medical aesthetic products target a range of procedures, from permanent hair reduction to muscle stimulation. Their focus on innovation and expanding their product offerings has contributed to their growth in the healthcare equipment industry.
Analyzing the technical data, INMDs stock is currently trading at $13.28, with its 52-week low. The SMA20 and SMA50 are at $14.16 and $14.55, respectively, indicating a potential resistance level. The SMA200 is at $16.87, suggesting a longer-term downtrend. The ATR is 0.42, representing a 3.19% daily volatility. Based on this data, a potential trading strategy could be to wait for a breakout above the SMA20 or SMA50, or to short-sell if the stock continues to trend downwards.
From a fundamental perspective, InModes market capitalization is approximately $902.94M USD, with a P/E ratio of 6.52 and a forward P/E of 8.70. The companys RoE is 25.01%, indicating a relatively high return on equity. Considering these metrics, a forecast for INMDs stock price could be influenced by its ability to maintain its RoE and grow its revenue. If the company continues to innovate and expand its product offerings, it may lead to increased revenue and a higher stock price. However, if the current downtrend continues, it may result in further declines.
Combining both technical and fundamental analysis, a potential forecast for INMDs stock price could be a short-term trading range between $13.28 and $14.55, with a potential breakout or breakdown. In the longer term, if InMode continues to demonstrate strong financials and innovate in the medical technology space, its stock price may recover and potentially exceed its 52-week high of $19.53. Conversely, if the company fails to meet expectations or faces increased competition, its stock price may continue to decline.
Additional Sources for INMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
INMD Stock Overview
Market Cap in USD | 889m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2019-08-08 |
INMD Stock Ratings
Growth Rating | -22.0 |
Fundamental | 54.4 |
Dividend Rating | 0.0 |
Rel. Strength | -8.71 |
Analysts | 3.43 of 5 |
Fair Price Momentum | 12.70 USD |
Fair Price DCF | 19.91 USD |
INMD Dividends
Currently no dividends paidINMD Growth Ratios
Growth Correlation 3m | -27.5% |
Growth Correlation 12m | -38.6% |
Growth Correlation 5y | -52.7% |
CAGR 5y | 1.24% |
CAGR/Max DD 5y | 0.01 |
Sharpe Ratio 12m | 0.96 |
Alpha | -26.91 |
Beta | 1.060 |
Volatility | 39.68% |
Current Volume | 1756.3k |
Average Volume 20d | 1227.2k |
Stop Loss | 14.5 (-4.5%) |
As of July 12, 2025, the stock is trading at USD 15.18 with a total of 1,756,258 shares traded.
Over the past week, the price has changed by +0.13%, over one month by +4.26%, over three months by +7.66% and over the past year by -13.50%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, InMode (NASDAQ:INMD) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 54.38 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INMD is around 12.70 USD . This means that INMD is currently overvalued and has a potential downside of -16.34%.
InMode has received a consensus analysts rating of 3.43. Therefor, it is recommend to hold INMD.
- Strong Buy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, INMD InMode will be worth about 15 in July 2026. The stock is currently trading at 15.18. This means that the stock has a potential downside of -1.05%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 17.1 | 12.3% |
Analysts Target Price | 17.3 | 13.6% |
ValueRay Target Price | 15 | -1.1% |